Ejung Moon is a Group Leader in Radiation Biology and the Tumour Microenvironment at the Department of Oncology, University of Oxford's Medical Sciences Division. Her research focuses on hypoxia-driven tumor progression and radiation response mechanisms. Education: PhD in Pharmacology and Cancer Biology from Duke University Training: Postdoctoral work with Amato Giaccia at Stanford University Research Interests: Elucidating how hypoxia-induced MAFF protein regulates tumor cell invasion, metastasis, and radiation resistance through antioxidant response pathways. Current work explores MAFF dimerization dynamics and metabolic reprogramming in hypoxic tumors. Scientific Contributions: Identified MAFF's role in radiation-induced antioxidant gene regulation (2021, Nature Communications ). Recent studies investigate iron metabolism's impact on FLASH radiotherapy effects. Scientific Awards: Breast Cancer Research Program (BCRP) predoctoral fellowship Laboratory & Collaborations: Moon Lab collaborates with Oxford Cancer and NHS Cancer and Haematology Centre. Key partnerships include Stanford University's radiobiology research groups.
John Oakey is a Professor and Graduate Coordinator in the Department of Chemical and Biomedical Engineering at the University of Wyoming, with additional affiliations to the INBRE Program, Molecular and Cellular Life Sciences Program, and Materials Science and Engineering Program. Education Postdoctoral Fellow, Center for Engineering in Medicine, Massachusetts General Hospital & Harvard Medical School (2007–2010) Ph.D. Chemical Engineering, Colorado School of Mines (2003) M.S. Chemical Engineering, Colorado School of Mines (1999) B.S. Chemical Engineering, Penn State University (1997) Research Interests Oakey’s laboratory integrates fluid dynamics, colloidal science and materials science to understand how biological systems behave under flow, on surfaces and within complex 3-D geometries. A unifying theme is the use of microfabrication and microfluidics to create new diagnostic, prognostic and therapeutic platforms. Current thrusts include: Heterogeneous biomaterials: self-assembled particulate tissue scaffolds whose mechanical and transport properties can be temporally programmed. Inertial microfluidics: exploiting lift forces for membrane-free particle sorting, enrichment and diagnostics. Multi-temporal analysis by flow cytometry: development of closed-loop, high-throughput microfluidic cytometers for longitudinal single-cell studies. Publication Trends From 2025 back to 2010, Oakey’s articles reveal a consistent trajectory that marries fundamental physics (microtubule mechanics, inertial focusing) with translational applications (cell encapsulation, tissue scaffolds, drug delivery). Recent work (2023-2025) increasingly targets injectable granular hydrogels, single-cell therapeutic delivery and sustainable carbon-sequestering living materials, demonstrating an evolution from microscale transport phenomena to macroscopic biomedical and environmental impact. Scientific Awards No named awards are listed in the supplied text. Advising & Coordination Roles As Graduate Coordinator for the Department of Chemical and Biomedical Engineering, Professor Oakey oversees graduate program development and student mentoring. While no individual students are named, his role implies active supervision of M.S. and Ph.D. advisees in chemical and biomedical engineering. Laboratory & Teams The Oakey Research Group operates from the Energy and Environmental Research Building (EERB 435A) at the University of Wyoming. The lab enjoys R1-level research infrastructure and collaborates broadly with the Wyoming INBRE network, the Molecular and Cellular Life Sciences Program, and the Materials Science and Engineering Program.
Ting Lu is an Associate Professor at the University of Illinois at Urbana-Champaign in the School of Biomedical and Translational Sciences, focusing on microbial synthetic biology and systems biology. Their research bridges biology, engineering, and physics to reprogram cellular functionalities through gene regulatory networks. Ph.D. in Biophysics, University of California at San Diego (2007) B.S. in Physics, Zhejiang University (2002) Ting Lu's work explores microbial ecosystems, synthetic gene circuits, and their applications in biotechnology and medicine. By combining experimental approaches with mathematical modeling, they investigate bacterial communication networks, metabolic pathways, and spatial dynamics in microbial communities. Selected research trends include microbial consortia engineering for bioremediation and bioproduction, complexity reduction in microbiomes, and predictive modeling of synthetic gene networks. Their publications span high-impact journals such as Nature Communications , Nature Chemical Biology , and eLife . Fellow, American Institute for Medical and Biological Engineering (2022) Future Insight Prize (2021) Donald Biggar Willett Faculty Scholar (UIUC) (2020) NIH Maximizing Investigators' Research Award (2019) NSF CAREER Award (2015) AHA National Scientist Development Grant (2012) Ting Lu's lab has received grants from NIH, NSF, ONR, and industry partners. They offer undergraduate research opportunities in synthetic and systems biology, and teach advanced courses such as BIOE 430 - Intro Synthetic Biology and BIOE 432 - Systems Biology .
Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Zhe Ji is an Assistant Professor in the Department of Biomedical Engineering at McCormick School of Engineering and the Department of Pharmacology at Feinberg School of Medicine, Northwestern University. His research integrates computational and experimental genomics to study gene transcription and RNA translation in cell fate commitment and oncogenic processes, aiming to develop precision medicine strategies. **Education**: Postdoctoral Fellow in Cancer Systems Biology, Harvard Medical School Postdoctoral Fellow in Computational Biology, Broad Institute of MIT and Harvard Ph.D. in Computational Genomics, Rutgers University B.S. in Biotechnology, Nanjing University, China **Research Focus**: Keywords include Data Science, Computational Biology, Functional Genomics, RNA, Cancer, Inflammation, and Machine Learning. The lab explores regulatory mechanisms underlying disease, with a focus on translational control, cancer metastasis, and inflammatory networks. **Grants & Advising**: No specific grants or student advisees listed. The lab emphasizes collaborative projects and computational-experimental approaches. **Lab Affiliations**: Zhe Ji’s lab is part of Northwestern’s interdisciplinary environment, bridging engineering and medicine to advance genomic technologies and therapeutic strategies.
Virgil Percec is the P. Roy Vagelos Professor of Chemistry at the University of Pennsylvania, affiliated with the School of Arts & Sciences and the Department of Chemistry. His research focuses on organic, supramolecular, and macromolecular chemistry, with an emphasis on self-assembly, drug delivery systems, and biomimetic nanosystems. He holds a B.S. and Ph.D. from institutions in Jassy, Romania, and conducted postdoctoral research at the University of Freiburg and the University of Akron. Research Interests: Percec’s work integrates synthetic methods, catalysis, and structural biology to design functional nanosystems. Key areas include hierarchical folding, supramolecular chirality, and synthetic mimics of biological membranes. His lab explores mRNA delivery systems using Janus dendrimers and studies self-organized structures like helical columns and quasicrystals. Recent Articles: His recent publications highlight advancements in mRNA delivery mechanisms, supramolecular architectures, and polymer synthesis innovations. The group’s work often involves interdisciplinary collaborations, bridging chemistry, materials science, and bioengineering. Awards: Percec was elected a Foreign Member of the Academia Europaea (2020) and delivered the inaugural ACS Kavli Lecture (2011). His lab has trained numerous students and postdocs, including Juncheng Lu (Master’s Capstone Award recipient) and Devendra Maurya (SET-LRP research). Labs & Teams: The Percec Research Laboratory at Penn develops cutting-edge biomaterials and supramolecular systems. The group collaborates globally, with projects funded by grants exploring nanotechnology and drug delivery.
Sara Gallini is an Assistant Professor at EPFL, leading the Gallini Lab within the ISREC Department of the School of Engineering (SV). Her research focuses on understanding how healthy and oncogenic cells compete in skin epithelium, aiming to identify therapeutic targets for skin cancer prevention. She holds a Tenure Track position and teaches in the Life Sciences Engineering program. Her lab employs advanced in vivo imaging and single-cell analysis techniques. Education details are not explicitly provided, but her career includes a postdoctoral fellowship with the HFSP. Her research integrates molecular, cellular, and systems-level approaches to study cancer initiation and tissue homeostasis, particularly in injury-driven dynamics. Lab Members: Includes PhD student Mustafa Öztürk and technical staff Mélanie Sipion. Key Research Themes: Oncogenic cell competition, epidermal regeneration, EGFR/ERK signaling, and therapeutic target discovery. Her lab collaborates with clinical teams and uses models like mouse skin to study tumor suppression mechanisms. Future work aims to leverage healthy cell dynamics for cancer treatment strategies. Contact: SV 2527 office, +41216936764, sara.gallini@epfl.ch .
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Lauren Andrews serves as Associate Professor and Marvin and Eva Schlanger Faculty Fellow in the Department of Chemical Engineering at the University of Massachusetts Amherst. Her research integrates synthetic biology and genetic engineering to develop programmable cellular systems for biotechnological applications. Education: Postdoctoral Training: Massachusetts Institute of Technology (Biological Engineering and Broad Institute of MIT and Harvard) PhD: University of Colorado Boulder, Chemical Engineering (2012) MS: University of Colorado Boulder, Chemical Engineering (2009) BS: Cornell University, Chemical Engineering (2006) Dr. Andrews' research focuses on establishing genetic design rules for reprogramming cellular regulation and metabolism. Her lab pioneers synthetic gene networks, genetically-encoded biosensors, and high-throughput methodologies for optimizing genetic designs in both model and non-model bacteria. This work enables precise control of cellular sensing, memory, and environmental responses through multiplexed DNA assembly and next-generation sequencing. Analysis of her 15 most recent publications reveals dominant themes in bacterial biosensor development (particularly for bioremediation), quorum sensing engineering, and programmable genetic circuits for probiotic applications. Her research consistently bridges fundamental genetic circuit design with practical implementations in bacterial consortia and non-model organisms. Scientific Awards: Marvin and Eva Schlanger Faculty Fellowship NSF CAREER Award (2020) for "Programmable synthetic microbial consortia for complex multicellular functions" Her grant portfolio demonstrates significant funding for collaborative research in bacterial communication systems and model-guided design of synthetic ecosystems. The Andrews Lab maintains active partnerships with the MIT-Broad Foundry and Cold Spring Harbor Laboratory, where she co-founded the Synthetic Biology Summer Course. Current projects focus on CRISPR-based regulation in non-model bacteria and algorithmic programming of sequential logic in probiotic strains. The Andrews Lab operates within the Life Science Laboratories at UMass Amherst, utilizing advanced facilities for genetic prototyping and high-throughput screening. Her team develops multiplexed tools for exploring genetic design spaces, with particular emphasis on soil bacteria and Gram-positive pathogens for environmental and therapeutic applications.
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
